However, in line with the in vivo tumor growth data, we did not observe any significant differences in CD8+ T cell infiltration in MC38 and CT26 tumors with ST3Gal5-deficiency compared to the MOCK control tumors. The gene discussed is CD8A; the disease is neoplasm.